Popular weight loss shots carry significant risk for some patients and doctors often fail to discuss those risks with ...

Popular weight loss shots carry significant risk for some patients and doctors often fail to discuss those risks with ...

The use of any GLP-1 RA, but particularly semaglutide and liraglutide, was associated with an increased risk for nonarteritic anterior ischemic optic neuropathy compared with other second-line ...

An increased risk for nonarteritic anterior ischemic optic neuropathy was seen in association with 2 GLP-1 RAs: semaglutide and liraglutide. HealthDay News — For older adults with type 2 diabetes, ...

A Medicare cohort study of nearly 4 million older patients with type 2 diabetes found 2 in 1000 developed nonarteritic anterior ischemic optic neuropathy (NAION) over a period of more than 3 years.

About The Study: This study of Medicare enrollees age 65 or older with type 2 diabetes found an association between semaglutide use and an increased risk of nonarteritic anterior ischemic optic ...

Nonarteritic anterior ischemic optic neuropathy (NAION), which can lead to vision loss, is a “very rare” side effect of treatment with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide, ...

June 6 (Reuters) - Novo Nordisk's (NOVOb.CO), opens new tab popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition that can lead to vision loss, ...

The lawsuits allege that Ozempic causes a rare eye condition called NAION, or non-arteritic anterior ischemic optic neuropathy, which is akin to an eye stroke. All but one of the cases were filed this ...

A Maryland man who took Ozempic and then became legally blind is suing the drug’s manufacturer, arguing it had an obligation to warn patients that loss of sight could be a possible side effect. Todd ...